Cardiac Dimensions said this week that it tapped the former chief of AccessClosure, Gregory Casciaro, to be its new president & CEO.
Casciaro led AccessClosure until its May 2014 acquisition by Cardinal Health (NYSE:CAH) for $320 million. His résumé includes stints as the chief executive at drug-eluting stent maker Xtent, Orquest (acquired JNJ’s DePuy Acromed in 2003) and General Surgical Innovations (acquired by U.S. Surgical for $100 million in 1999).
Cardiac Dimensions is developing the Carillon mitral valve, which is designed to treat functional mitral regurgitation. In March, the Kirkland, Wash.-based company raised a $15 million round. Carillon won CE Mark approval in the European Union in 2011.
“With more than 33 years of medical device experience and a proven track record of success leading both private and public companies, Greg will be instrumental in guiding the future strategic direction of Cardiac Dimensions,” said Jan Garfinkle, member of Cardiac Dimensions’ Board of Directors. “Based on his extensive knowledge of the interventional cardiology space, we believe he is the ideal choice to take Cardiac Dimensions to the next level.”
“Cardiac Dimensions has an innovative platform that is designed to address the unmet needs of heart failure patients and the related condition of FMR,” Casciaro added. “The clinical data available for this therapy have demonstrated that it benefits patients significantly and, we believe, holds incredible promise for the future. I am excited to lead this talented team forward as we increase access to the therapy through continued global commercialization and expanded clinical work.”
Grifols plans family succession
Grifols (NSDQ:GRFS) chairman & CEO Víctor Grifols is stepping down, to be replaced by his brother, Raimon Grifols, and son Víctor Grifols, effective January 2017.